Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval

 
• By Alex Shimmings
Swimmers swimming in lanes
Alecensa has a competitive edge in ALK-positive NSCLC • Source: Shutterstock

More from New Products

More from Scrip